Literature DB >> 8827629

Sonicated albumin in exercise echocardiography: technique and feasibility to enhance endocardial visualization.

K J Yvorchuk1, R A Sochowski, K L Chan.   

Abstract

Left ventricular cavity opacification can be produced by the intravenous injection of sonicated albumin (Albunex 422). A recent study suggested that sonicated albumin may be useful in dobutamine stress echocardiography, but its use in exercise echocardiography has not been reported. The purposes of the study were to assess the feasibility of using Albunex to enhance endocardial visualization and to evaluate the factors affecting Albunex kinetic in exercise echocardiography. Fifteen healthy volunteers underwent two exercise echocardiograms on the same day, with intravenous injection of Albunex during one of the studies. Two injections up to a maximum of 20 ml of Albunex per injection were given to enhance the four- and two-chamber views, both at rest and immediately after exercise. The degree of left ventricular enhancement and the percentages of endocardial visualization were measured in both resting and exercise images. Variables relating to the kinetics of Albunex, which included volume of contrast injected, transit time, heart rate, and cardiac output at the time of image acquisition, were also assessed. There was no difference in the image acquisition time between the two exercise echocardiograms. Albunex produced good left ventricular opacification both at rest and after exercise. More endocardial border was visualized with contrast injection than without (91.2% +/- 11.5% vs 85.8% +/- 14.2%, p = 0.007). The transit times and volumes of Albunex injected were significantly less after exercise than at rest. The parameters were inversely related to heart rate and cardiac output. In conclusion, intravenous injection of Albunex is a promising means to enhance left ventricular endocardial visualization in exercise echocardiography and can be readily incorporated without causing a significant delay in obtaining images after exercise. Whether its use can improve diagnostic accuracy of exercise echocardiography requires further studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827629     DOI: 10.1016/s0894-7317(96)90117-0

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  2 in total

Review 1.  New ultrasound contrast agents for left ventricular and myocardial opacification.

Authors:  J D Kasprzak; F J Ten Cate
Journal:  Herz       Date:  1998-12       Impact factor: 1.443

Review 2.  Perflenapent emulsion (EchoGen): a new long-acting phase-shift agent for contrast echocardiography.

Authors:  P Grayburn
Journal:  Clin Cardiol       Date:  1997-10       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.